Literature DB >> 15110528

Specific antibodies modulate the interactions of adenovirus type 5 with dendritic cells.

S Mercier1, H Rouard, M H Delfau-Larue, M Eloit.   

Abstract

Adenovirus type 5 (Ad5) is able to induce an efficient CD8+ T lymphocyte (CTL) response against a transgene product, a property thought to be linked to its ability to transduce dendritic cells (DCs). Little, however, is known about the capacity of Ad5 to interact with DCs in the presence of specific antibodies, although most people test positive for antibodies directed against Ad5. In the present study, we found that in the presence of Ad5 antibodies, a large fraction of Ad5 binds very efficiently to DCs, and that this binding is FcgammaRII/FcgammaRIII dependent. Nevertheless, in the presence of high levels of antibodies against the whole virion, Ad5 entry was inhibited. Increased binding led to increased entry in DCs in the presence of fiber-specific antibodies or in the presence of low amounts of a whole antiserum raised against whole virions, showing that the relative concentration of antibodies directed against fiber and penton base plays a major role in entry efficacy. Nevertheless, mice previously immunized with virions or purified fiber developed a lower transgene-specific CD8+ T cell response than naive mice, although their serum appeared to increase virus entry into DCs in vitro.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15110528     DOI: 10.1016/j.virol.2004.01.031

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.

Authors:  J Melo-Cardenas; M Urquiza; T J Kipps; J E Castro
Journal:  Cancer Gene Ther       Date:  2012-03-09       Impact factor: 5.987

2.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1.

Authors:  Matthew J Cotter; Anne K Zaiss; Daniel A Muruve
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Early steps of clathrin-mediated endocytosis involved in phagosomal escape of Fcgamma receptor-targeted adenovirus.

Authors:  Oliver Meier; Michele Gastaldelli; Karin Boucke; Silvio Hemmi; Urs F Greber
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway.

Authors:  Philip L Leopold; Rebecca L Wendland; Theresa Vincent; Ronald G Crystal
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 6.  The influence of innate and pre-existing immunity on adenovirus therapy.

Authors:  Anne K Zaiss; Hidevaldo B Machado; Harvey R Herschman
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

7.  Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells.

Authors:  Ramil Sapinoro; Ketna Volcy; W W Shanaka I Rodrigo; Jacob J Schlesinger; Stephen Dewhurst
Journal:  Virology       Date:  2008-01-14       Impact factor: 3.616

8.  Serotype chimeric human adenoviruses for cancer gene therapy.

Authors:  Tuuli Ranki; Akseli Hemminki
Journal:  Viruses       Date:  2010-09-30       Impact factor: 5.818

Review 9.  Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism.

Authors:  Craig Schindewolf; Vineet D Menachery
Journal:  Viruses       Date:  2019-01-17       Impact factor: 5.048

10.  Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach.

Authors:  Qiana L Matthews; PingAr Yang; Qi Wu; Natalya Belousova; Angel A Rivera; Mariam A Stoff-Khalili; Reinhard Waehler; Hui-Chen Hsu; Zan Li; Jing Li; John D Mountz; Hongju Wu; David T Curiel
Journal:  Virol J       Date:  2008-08-21       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.